Highbridge Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Highbridge Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-90,000	Closed	-$7.66M	–	437
2018 Q4	$6.46M	Buy	+90,000	New	+$7.25M	0.19%	137
2017 Q3	–	Sell	-50,000	Closed	-$4.01M	–	1815
2017 Q2	$3.86M	Buy	+50,000	New	+$3.55M	0.06%	336

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return

Highbridge Capital Management's XBI Position: Q1 2019 in Review

Highbridge Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2019, closing a stake of 90,000 shares — an estimated $7.66M sold.

Highbridge Capital Management first reported a position in XBI in Q2 2017 and held it in 2 quarters. The position peaked at $6.46M in Q4 2018. 451 funds tracked by Wall St. Rank hold XBI as of Q1 2019.

Highbridge Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2019 after selling out during the quarter.
Highbridge Capital Management sold 90,000 State Street SPDR S&P Biotech ETF shares in Q1 2019, an estimated $7.66M.
Highbridge Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and held it in 2 quarters.
Highbridge Capital Management's State Street SPDR S&P Biotech ETF position peaked at $6.46M in Q4 2018.
451 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2019.

Based on Highbridge Capital Management's 13F filing for Q1 2019, filed 15 May 2019.